Showing results (131-140 of 150) with videos related to
Sort By:
Pageof 15
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 4, 2026
Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cellsLauren Sarko, David Givand, Brendan Rattin, et al.Journal of Clinical Medicine|January 8, 2023
Differential Effects of Patient Navigation across Latent Profiles of Barriers to Care among People Living with HIV and Comorbid ConditionsSharleen M Traynor, Renae D Schmidt, Lauren K Gooden, et al.Clinical Lymphoma, Myeloma & Leukemia|December 2, 2017
VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network StudyJulie E Chang, Lakeesha L Carmichael, KyungMann Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network studySteven Attia, Anne M Traynor, Kyungmann Kim, et al.Plos One|July 27, 2016
High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1Jennifer L Schehr, Zachery D Schultz, Jay W Warrick, et al.International Journal of Radiation Oncology, Biology, Physics|December 10, 2023
Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b TrialMichael F Bassetti, Brett A Morris, Nan Sethakorn, et al.Cancer|January 29, 2013
An eHealth system supporting palliative care for patients with non-small cell lung cancer: a randomized trialDavid H Gustafson, Lori L DuBenske, Kang Namkoong, et al.Cancer|June 17, 2015
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network studyTimothy S Fenske, Namrata M Shah, Kyung Mann Kim, et al.Investigational New Drugs|June 4, 2013
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II studyTien Hoang, Toby C Campbell, Chong Zhang, et al.Investigational New Drugs|October 12, 2013
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignanciesWilliam R Schelman, Anne M Traynor, Kyle D Holen, et al.Pageof 15